Lumbrokinase for Poor Circulation

Lumbrokinase is used for poor circulation on the basis of its fibrinolytic activity and a substantial body of Chinese hospital studies in ischaemic conditions. The direction of effect is consistent — lower fibrinogen, reduced platelet aggregation, improved flow measures — but the trials are small and methodologically weak, so confidence stays low.

Lumbrokinase enzymes hydrolyse fibrin directly and also activate plasminogen to plasmin, amplifying the body's own clot-dissolving system. Reported downstream effects include reduced plasma fibrinogen, lower whole-blood viscosity and decreased platelet aggregation, all of which would plausibly improve microcirculatory flow.

The evidence base is unusual: hundreds of Chinese-language clinical reports covering ischaemic stroke, unstable angina, diabetic vascular complications and hyperviscosity syndromes, most reporting benefit on haemorheological measures. A frequently cited multicentre study in ischaemic stroke reported improved neurological scores versus control. Against that, few studies are properly randomized or blinded, outcome reporting is inconsistent, publication bias in this literature is well documented, and there is no large Western trial or regulatory approval. Direct head-to-head data against aspirin or standard anticoagulation does not exist. The honest position is that a plausible mechanism plus a large weak literature equals mixed: worth discussing with a clinician for circulation support in someone not already anticoagulated, and not defensible as a replacement for proven therapy in anyone with a diagnosed clotting or cardiovascular condition.

People whose circulation problems are structural — significant atherosclerotic stenosis, venous valve incompetence or lymphoedema — will not get meaningful benefit from a fibrinolytic enzyme.